Featuring an interview with Dr Hope S Rugo, including the following topics:

• Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00)
• Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03)
• Management of common toxicities with approved ADCs (10:48)
• Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17)
• Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09)

CME information and select publications